-
Transplant International : Official... Jun 2016Vascularized composite allografts (VCAs) are a growing field within the area of transplantation. In 2014, the birth of a healthy baby after a successful uterus... (Review)
Review
Vascularized composite allografts (VCAs) are a growing field within the area of transplantation. In 2014, the birth of a healthy baby after a successful uterus transplant from a living donor was reported in Sweden. VCAs are not specifically mentioned in any of the transplant acts of the Eurotransplant (ET) member states, which all belong to the European Union (EU). The Competent Authorities (CA) of the EU decided in 2012 that VCAs are to be regarded as organs. At the moment, there are no general guidelines in the ET area concerning wait list registration, allocation, procurement and transplantation, and also no regulations concerning reimbursement. To further develop this aspect, common policies and guidelines within the ET member states have to be developed.
Topics: Composite Tissue Allografts; Europe; Female; Graft Rejection; Graft Survival; Humans; Immune Tolerance; Skin Transplantation; Tissue and Organ Procurement; Transplantation Chimera; Transplantation, Homologous; Uterus; Vascularized Composite Allotransplantation
PubMed: 26824440
DOI: 10.1111/tri.12753 -
International Journal of Surgery... Oct 2020Dynamic preservation strategies are a promising option to improve graft quality before transplantation, and to extend preservation time for either logistic or treatment... (Review)
Review
Dynamic preservation strategies are a promising option to improve graft quality before transplantation, and to extend preservation time for either logistic or treatment reasons. In contrast to normothermic oxygenated perfusion, which intends to mimic physiological conditions in the human body, with subsequent clinical application for up to 24 hrs, hypothermic perfusion is mainly used for a relatively short period with protection of mitochondria and subsequent reduction of oxidative injury upon implantation. The results from two randomized controlled trials, where recruitment has finished are expected this year. Both ex situ perfusion techniques are increasingly applied in clinical transplantation including recent reports on viability assessment, which could open the door for an increased liver utilization in the future.
Topics: Humans; Hypothermia, Induced; Liver; Liver Transplantation; Organ Preservation; Perfusion; Transplants; Treatment Outcome
PubMed: 32353556
DOI: 10.1016/j.ijsu.2020.04.057 -
Ugeskrift For Laeger Apr 2023Since the first kidney transplant was conducted in Denmark in 1964, almost 10,000 transplants have been performed. Graft survival has improved over the past two decades... (Review)
Review
Since the first kidney transplant was conducted in Denmark in 1964, almost 10,000 transplants have been performed. Graft survival has improved over the past two decades despite the increase in age and comorbidities in both donors and recipients, but organ shortage remains a challenge. The focus of this review is to describe the challenges in kidney transplant and highlight the progress achieved in solving these challenges.
Topics: Humans; Kidney Transplantation; Living Donors; Tissue Donors; Tissue and Organ Procurement; Transplants; Denmark; Registries
PubMed: 37057695
DOI: No ID Found -
Hematology/oncology and Stem Cell... Dec 2017Algeria is a country of 40.4 million inhabitants and half of which is under 30years. In Algeria, Health-care insurance covered, 90% of the population. Health care is... (Review)
Review
INTRODUCTION
Algeria is a country of 40.4 million inhabitants and half of which is under 30years. In Algeria, Health-care insurance covered, 90% of the population. Health care is free and it is supported by the Ministry of Health. 16 university hospitals exist in Algeria and only two (Algiers and Oran) practicing bone marrow transplant. Adult hematologic malignancies account for 10% (about 4000 new cases/year) of the malignancy affecting in most cases young patients under 65years of age. In 2016, 270 transplants were performed in total (Algiers+Oran), including 149 allografts (related donor transplants: 99%) and 121 autografts. 98% of transplants are done in adults and only 2% in children with cord blood transplants. In summary for the two transplant centers, the predominant types of transplantation performed are allogeneic transplant in 55% and autologous transplant in 45%. The particularity of EHU1st November in Oran, is the use of non-cryopreserved stem cells. Stem cell was mobilized using G-CSF alone and the grafts were kept in a conventional blood bank refrigerator at +4°C until reinfusion on day 0. The outcome with non-cryopreserved stem cells are the same as those with cryopreserved stem cells and we conclude that autologous transplant with non cryopreserved hematopoietic stem cells (HSC) is a simple, effective and safe method and the cryopreservation is not necessary in our work conditions in developing countries. The projects are achieving the autograft in all University Hospitals with non cryopreserved HSC, achieving a center allograft in the east of the country and the development of bone marrow transplantation in children.
CONCLUSION
Currently in Algeria, the number of transplantation is insufficient and the development of new transplant centers is essential. In the future, we hope to implement the National Society of Bone Marrow transplant and also the National recipient registry and Donor registry in Algeria.
Topics: Adult; Aged; Algeria; Allografts; Autografts; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hospitals, Teaching; Humans; Male; Middle Aged; Survival Rate
PubMed: 28711452
DOI: 10.1016/j.hemonc.2017.05.019 -
Transplant International : Official... Jul 2018More than thirty-five facial allograft transplantations (FAT) have been reported worldwide since the pioneering case performed in France in the year 2005. FAT has... (Review)
Review
More than thirty-five facial allograft transplantations (FAT) have been reported worldwide since the pioneering case performed in France in the year 2005. FAT has received tremendous interest by the medical field and the general public while gaining strong support from multiple disciplines as a solution for reconstructing complex facial defects not amenable/responsive to conventional methods. FAT has expanded the frontiers of reconstructive microsurgery, immunology and transplantation, and established its place in the cross section of multiple disciplines. The procedure introduces complex scientific, ethical, and societal issues. Patients and physicians are called to deal with a variety of-sometimes everlasting-challenges, such as immunosuppression management and psychosocial hurdles. This review reflects on the surgical and scientific advancements in FAT and milestones reached in the last 12 years. It aims to encourage active discussion regarding the current practices and techniques used in FAT and suggest future directions that may allow transitioning into the next phase of FAT, which we describe as safe, reliable, and accessible standard operation for selected patients.
Topics: Allografts; Facial Transplantation; Humans; Patient Selection; Transplantation Immunology; Treatment Outcome
PubMed: 29421860
DOI: 10.1111/tri.13130 -
The Journal of Clinical Investigation Jan 2019Donor age and recipient age are factors that influence transplantation outcomes. Aside from age-associated differences in intrinsic graft function and alloimmune... (Review)
Review
Donor age and recipient age are factors that influence transplantation outcomes. Aside from age-associated differences in intrinsic graft function and alloimmune responses, the ability of young and old cells to exert either rejuvenating or aging effects extrinsically may also apply to the transplantation of hematopoietic stem cells or solid organ transplants. While the potential for rejuvenation mediated by the transfer of youthful cells is currently being explored for therapeutic applications, aspects that relate to accelerating aging are no less clinically significant. Those effects may be particularly relevant in transplantation with an age discrepancy between donor and recipient. Here, we review recent advances in understanding the mechanisms by which young and old cells modify their environments to promote rejuvenation- or aging-associated phenotypes. We discuss their relevance to clinical transplantation and highlight potential opportunities for therapeutic intervention.
Topics: Aging; Allografts; Animals; Cellular Microenvironment; Cellular Senescence; Hematopoietic Stem Cell Transplantation; Humans; Organ Transplantation; Tissue Donors
PubMed: 30601138
DOI: 10.1172/JCI123946 -
American Journal of Transplantation :... Oct 2022
Topics: Cell Engineering; Kidney Transplantation; Transplants; United States
PubMed: 36196493
DOI: 10.1111/ajt.16675 -
Transplantation Oct 2020
Topics: Composite Tissue Allografts; Vascularized Composite Allotransplantation
PubMed: 32039964
DOI: 10.1097/TP.0000000000003165 -
Hematology/oncology and Stem Cell... Dec 2017Thalassemia is the most common monogenic hematologic disease that affects millions in the world and kills thousands of patients every year. Without transfusion or... (Review)
Review
Thalassemia is the most common monogenic hematologic disease that affects millions in the world and kills thousands of patients every year. Without transfusion or transplantation, patients with thalassemia major are expected to die within months of diagnosis. However, long-term transfusion and chelation therapy is highly challenging for many developing countries where the disease is prevalent, representing a major and unsustainable health burden. Stem cell transplantation is the only cure for thalassemia. It has witnessed major developments that have made it less toxic, more successful, and feasible for a larger number of patients with diverse comorbidities and from a wider range of donors. Advances in human leukocyte antigen typing have greatly refined alternate donor selection with results of matched unrelated donors similar to matched sibling donors. Novel strategies such as haploidentical and cord blood transplantation have increased the possibility of patients with no healthy donor to get a better opportunity to survive and avoid chronic transfusion complications. Cost-effectively, transplantation should be considered the primary treatment of choice in the presence of a suitable related or unrelated donor and at centers with a satisfactory experience in the field of transplantation and particularly, in managing those with thalassemia. Despite some complications such as graft-versus-host disease and late conditioning effects, the overall improvement in the quality of life of thalassemia is difficult to deny. Unfortunately, the number of transplants for thalassemia represents only a minority of all transplants conducted globally and the essential requirement for transplants for thalassemia in limited-resources countries should mandate the transplant societies, including Worldwide Network for Blood and Marrow Transplantation, to collaborate to help initiate and support specialized transfusion and transplant programs for managing thalassemia.
Topics: Allografts; Blood Transfusion; Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Humans; Iron Chelating Agents; beta-Thalassemia
PubMed: 28651066
DOI: 10.1016/j.hemonc.2017.05.022 -
American Journal of Transplantation :... Jul 2021
Topics: Humans; Lung Transplantation; Palliative Care; Transplants
PubMed: 34196485
DOI: 10.1111/ajt.16035